4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $2.83 | $3.57 | +26.3% | Beat |
| Q4 2025 | 2025-12-31 | $1.65 | $1.99 | +20.9% | Beat |
| Q3 2025 | 2025-09-30 | $3.96 | $4.81 | +21.5% | Beat |
| Q2 2025 | 2025-06-30 | $3.94 | $5.47 | +38.9% | Beat |
Earnings Beat Rate
Biogen has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →